View all results
Noticia de prueba
11 December 2023
Almirall, Barcelona Supercomputing Center (BSC) and Nostrum Biodiscovery collaborate to seek new therapies through AI
16 November 2023
Almirall receives European Commission approval of EBGLYSS® (lebrikizumab) for moderate-to-severe atopic dermatitis
View all press
We are going to take you to a different platform
This platform is safe as takes part of Almirall ecosystem
You are about to leave www.almirall.com
Specific policies may apply to the site you are visiting; all interaction with that site is at your own risk.
The content you are about to see is restricted to media professional use
Please let us know if you are a professional to continue.
I'm a media professional
The content you are about to see is restricted to HC Professional use only
Please let us know if you are a HC Professional to continue.
I'm a HC Professional